Moreover, recognizing the intricate landscape of the tumor microenvironment, a combinatorial approach integrating the CARD11-PIK3R3 fusion gene with other immunotherapeutic modalities, such as immune checkpoint blockade (ICB) and costimulatory receptor activation, warrants exploration to engender synergistic anti-tumor effects. The gene discussed is PIK3R3; the disease is neoplasm.